Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF, Aboudara M, Hoffmann Filho CR, Feitosa ADM, Fonseca A, Garla V, Gordon RA, Javaheri A, Jaeger CP, Leaes PE, Nassif M, Pursley M, Silveira FS, Barroso WKS, Lazcano Soto JR, Nigro Maia L, Berwanger O

Open source

DOI: 10.1016/s2213-8587(21)00180-7
Published: 2021 Sep
Container: The lancet. Diabetes & endocrinology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-8587-21-00180-7,
  title = {Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.},
  author = {Kosiborod MN and Esterline R and Furtado RHM and Oscarsson J and Gasparyan SB and Koch GG and Martinez F and Mukhtar O and Verma S and Chopra V and Buenconsejo J and Langkilde AM and Ambery P and Tang F and Gosch K and Windsor SL and Akin EE and Soares RVP and Moia DDF and Aboudara M and Hoffmann Filho CR and Feitosa ADM and Fonseca A and Garla V and Gordon RA and Javaheri A and Jaeger CP and Leaes PE and Nassif M and Pursley M and Silveira FS and Barroso WKS and Lazcano Soto JR and Nigro Maia L and Berwanger O},
  year = {2021},
  journal = {The lancet. Diabetes \& endocrinology},
  doi = {10.1016/s2213-8587(21)00180-7},
  url = {https://doi.org/10.1016/s2213-8587(21)00180-7}
}

RIS

TY  - JOUR
TI  - Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
AU  - Kosiborod MN
AU  - Esterline R
AU  - Furtado RHM
AU  - Oscarsson J
AU  - Gasparyan SB
AU  - Koch GG
AU  - Martinez F
AU  - Mukhtar O
AU  - Verma S
AU  - Chopra V
AU  - Buenconsejo J
AU  - Langkilde AM
AU  - Ambery P
AU  - Tang F
AU  - Gosch K
AU  - Windsor SL
AU  - Akin EE
AU  - Soares RVP
AU  - Moia DDF
AU  - Aboudara M
AU  - Hoffmann Filho CR
AU  - Feitosa ADM
AU  - Fonseca A
AU  - Garla V
AU  - Gordon RA
AU  - Javaheri A
AU  - Jaeger CP
AU  - Leaes PE
AU  - Nassif M
AU  - Pursley M
AU  - Silveira FS
AU  - Barroso WKS
AU  - Lazcano Soto JR
AU  - Nigro Maia L
AU  - Berwanger O
PY  - 2021
JO  - The lancet. Diabetes & endocrinology
DO  - 10.1016/s2213-8587(21)00180-7
UR  - https://doi.org/10.1016/s2213-8587(21)00180-7
ER  -

APA

MN, K., R, E., RHM, F., J, O., SB, G., GG, K., F, M., O, M., S, V., V, C., J, B., AM, L., P, A., F, T., K, G., SL, W., EE, A., RVP, S., DDF, M., M, A., CR, H. F., ADM, F., A, F., V, G., RA, G., A, J., CP, J., PE, L., M, N., M, P., FS, S., WKS, B., JR, L. S., L, N. M., & O, B. (2021). Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.. The lancet. Diabetes & endocrinology. https://doi.org/10.1016/s2213-8587(21)00180-7

Source records

pubmed · retrieved 2026-09-27T08:17:55.743Z